EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy

Andres Chang, Adam N Pelletier, Donald J McGuire, Maria Tsagiopoulou, Maria Karipidou, Amy Ayers, Alyssa M K Leal, Michael C Churnetski, Colin B O'Leary, Jeffrey M Switchenko, Carl Davis, David A Frank und 6 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2426935122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Andres Chang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Programmed Cell Death 1 Receptor, Agammaglobulinaemia Tyrosine Kinase, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | National Institutes of Health (NIH), American Society of Hematology (ASH), EU | Winship Cancer Institute (Winship Cancer Institute of Emory University).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) remains incurable despite treatment advances, and a major challenge is that biomarkers that predict response and resistance to current therapies are lacking. We report that activated and proliferating malignant CLL B cells in circulation express PD-1, a protein normally expressed in T cells. PD-1 expression is absent in circulating B cells from healthy controls and nonmalignant B cells from patients with CLL. Circulating PD-1 + CLL cells are found in all treatment naïve patients, regardless of immunoglobulin heavy-chain variable region gene mutation status or cytogenetic abnormalities. PD-1 + CLL cells are transcriptionally distinct compared to PD-1 − CLL cells and upregulate genes associated with cell activation, proliferation, and B cell receptor (BCR) and toll-like receptor (TLR) signaling. Indeed, ex vivo stimulation of the BCR and TLR9 readily increased PD-1 expression in CLL cells from treatment-naïve patients within 24 h, an effect that was blocked by Bruton’s tyrosine kinase inhibitors (BTKi). More importantly, patients initiating BTKi therapy experienced profound reductions in circulating PD-1 + CLL cell numbers within 1 mo, which is in line with reduction in Ki-67 + CLL cells. Elevated percentages of circulating PD-1 + CLL cells also preceded a clinical diagnosis of disease progression in patients receiving BTKi. Thus, our findings indicate that PD-1 expression is a potential biomarker to identify proliferating CLL cells in vivo and will be useful to predict response and resistance to BTKi. In addition, eliminating PD-1 + CLL cells with depleting anti-PD-1 monospecific or bispecific antibodies should be explored as a potential therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellProgrammed Cell Death 1 ReceptorAgammaglobulinaemia Tyrosine KinaseBiomarkers, TumorProtein Kinase InhibitorsB-LymphocytesHumansCell ProliferationFemaleMaleAgedReceptors, Antigen, B-CellMiddle AgedToll-Like Receptor 9Aged, 80 and over

Stichwörter der Autor:innen

BTK inhibitorsPD-1biomarkerchronic lymphocytic leukemia

Substanzen

Programmed Cell Death 1 ReceptorAgammaglobulinaemia Tyrosine KinaseBiomarkers, TumorPDCD1 protein, humanProtein Kinase InhibitorsBTK protein, humanReceptors, Antigen, B-CellToll-Like Receptor 9

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
  • Institute of Applied Biosciences at the Centre for Research and Technology Hellas, Thessaloniki 57001, Greece.
  • Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322.

ORCID-Profile: Rafick P Sekaly

Förderung

  • HHS | National Institutes of Health (NIH)
  • American Society of Hematology (ASH)
  • EU | Winship Cancer Institute (Winship Cancer Institute of Emory University)
  • Hellenic Foundation for Research and Innovation (HFRI)
  • EC | ERC | HORIZON EUROPE European Research Council (ERC)
  • CLL Society
  • NIAID NIH HHS

Zitieren

APA

Chang, A., Pelletier, A. N., McGuire, D. J., Tsagiopoulou, M., Karipidou, M., Ayers, A., Leal, A. M. K., Churnetski, M. C., O'Leary, C. B., Switchenko, J. M., Davis, C., Frank, D. A., Koff, J. L., Cohen, J. B., Sekaly, R. P., Stamatopoulos, K., Flowers, C. R., & Ahmed, R. (2025). PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2426935122

Vancouver

Chang A, Pelletier AN, McGuire DJ, Tsagiopoulou M, Karipidou M, Ayers A, et al. PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2426935122

BibTeX
@article{Chang2025,
  author = {Chang, Andres and Pelletier, Adam N and McGuire, Donald J and Tsagiopoulou, Maria and Karipidou, Maria and Ayers, Amy and Leal, Alyssa M K and Churnetski, Michael C and O'Leary, Colin B and Switchenko, Jeffrey M and Davis, Carl and Frank, David A and Koff, Jean L and Cohen, Jonathon B and Sekaly, Rafick P and Stamatopoulos, Kostas and Flowers, Christopher R and Ahmed, Rafi},
  title = {PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2426935122}
}
Kostenlos starten →